×

USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA) AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUME CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS

  • US 20180236062A1
  • Filed: 02/25/2016
  • Published: 08/23/2018
  • Est. Priority Date: 02/25/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a solid malignant tumor in a subject in need thereof, the method comprising delivering to cells of the tumor a therapeutically effective amount of inactivated modified vaccinia Ankara virus (inactivated-MVA), thereby resulting in the treatment of the tumor.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×